Agenus Inc.

Equities

AGEN

US00847G8042

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
10.86 ^USD	+3.43%		+3.53%	-34.41%

05-16	Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	CI
05-07	Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	MT

Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 07, 2024 at 12:39 pm

Agenus Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 28.01 million compared to USD 22.9 million a year ago. Net loss was USD 61.89 million compared to USD 68.25 million a year ago.

Basic loss per share from continuing operations was USD 3.04 compared to USD 4.31 a year ago. Diluted loss per share from continuing operations was USD 3.04 compared to USD 4.31 a year ago.

Latest news about Agenus Inc.

Agenus Inc. announces FDA Grants Agenus Type B End-Of-Phase 2 Meeting to Discuss Bot/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer	05-16	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	05-07	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	05-07	MT
Transcript : Agenus Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M	05-07	MT
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Ligand and Agenus Enter into $100 Million Royalty Financing Agreement to Support Agenus? Key Development Initiatives in the Ongoing Bot/Bal Clinical Development Program	05-07	CI
Sector Update: Health Care Stocks Slipping Late Afternoon	04-12	MT
Sector Update: Health Care	04-12	MT
Agenus Shares Decline After Update on Early Stage Colorectal Cancer Drug Trial	04-12	MT
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	04-12	CI
Agenus Stockholders Approve 1-for-20 Reverse Stock Split	04-05	MT
B. Riley Securities Trims Agenus' Price Target to $5 From $6 After Model Update, Maintains Buy Rating	03-18	MT
Transcript : Agenus Inc., Q4 2023 Earnings Call, Mar 14, 2024	03-14
Earnings Flash (AGEN) AGENUS Posts Q4 Revenue $83.8M	03-14	MT
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Agenus Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
Agenus Inc. Announces Preclinical Data on BMS-986442 at AACR 2024	03-06	CI
Ginkgo Bioworks, Agenus Unit Win Contract to Discover, Develop Vaccine Adjuvants	02-15	MT
MiNK Therapeutics, Inc. announced that it has received $5 million in funding from Agenus Inc.	02-11	CI
Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer	12-20	CI
Agenus Inc.(NasdaqCM:AGEN) dropped from S&P Biotechnology Select Industry Index	12-18	CI
Agenus to Get $25 Million Milestone Payment From Bristol Myers Squibb Under AGEN1777 Licensing Deal	12-11	MT
B. Riley Lowers Agenus' Price Target to $6 From $8, Maintains Buy Rating	11-09	MT
Transcript : Agenus Inc., Q3 2023 Earnings Call, Nov 07, 2023	11-07

Chart Agenus Inc.

Duration

Period

More charts

Company Profile

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract No: 3556

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Agenus Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.86 USD

Average target price

44.25 USD

Spread / Average Target

+307.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AGENUS INC.	-34.41%	228M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research